| Literature DB >> 30076286 |
Natasa Nenadic-Baranasic1, Romana Gjergja-Juraski1,2, Ivan Lehman3, Mirjana Turkalj2,4, Boro Nogalo2,5, Nina Barisic3,6.
Abstract
BACKGROUND The aim of this study was to assess sleep architecture and respiration during sleep in children with intractable epileptic encephalopathies using overnight video-polysomnography (V-PSG). MATERIAL AND METHODS Between 2015 to 2017 overnight V-PSG recordings were made for 31 children (22 boys and 9 girls) with intractable epileptic encephalopathy with a mean age of 6.78±3.61 years and a mean body mass index (BMI) of 15.83±3.16 kg/m3. Thirty-one healthy children were matched for sex, age, and BMI as the control group. The phases of sleep studied included rapid eye movement (REM) sleep, and non-REM (NREM) phases NREM 1, NREM 2, and NREM 3. Respiratory function during sleep was evaluated. RESULTS Children with epileptic encephalopathies receiving antiepileptic treatment had significantly decreased total sleep time (TST) (p=0.038), significantly increased percentage of NREM1 (p=0.033), and a significantly lower percentage of total REM (p<0.0001), compared with the control group. All children 31/31 (100%) with epileptic encephalopathies had interictal epileptiform discharges, and 4/31 (12.9%) had ictal events. The number of respiratory events did not differ significantly between the two groups (p=0.118), but children in the epileptic encephalopathy group had a significantly shorter average duration (p=0.008) and longest duration (p=0.048) of respiratory events. Average (p=0.006) and least (p=0.0004) oxygen saturation (SatO2) were significantly lower in children with epileptic encephalopathies compared with the control group. CONCLUSIONS Children with epileptic encephalopathies had altered sleep architecture and marked oxygen desaturation, which supports the need for referral of children with epileptic encephalopathy for overnight sleep evaluation.Entities:
Mesh:
Year: 2018 PMID: 30076286 PMCID: PMC6089594 DOI: 10.12659/MSM.908911
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Demographic and clinical characteristics of children with epileptic encephalopathies.
| Age (years) (χ̄±SD) | 6.78±3.61 |
|
| |
| Male/Female | 22/9 |
|
| |
| Body Mass Index (kg/m2) (χ̄± SD) | 15.83±3.16 |
|
| |
| Cause of epileptic encephalopathies | |
| Structural | 13/31 (41.93%) |
| Genetic | 9/31 (29.03%) |
| Unknown | 9/31 (29.03%) |
|
| |
| Antiepileptic therapy | |
| Monotherapy | 7/31 (22.58%) |
| Polytherapy | |
| 2 antiepileptic drugs | 10/31 (32.25%) |
| 3 antiepileptic drugs | 8/31 (25.80%) |
| 4 antiepileptic drugs | 5/31 (16.13%) |
| Ketogenic diet | 1/31 (3.22%) |
|
| |
| Antiepileptic drugs | |
| Valproates | 17/30 (56.66%) |
| Clobazam | 14/30 (46.67%) |
| Levetiracetam | 7/30 (23.33%) |
| Oxcarbazepin | 6/30 (20.00%) |
| Topiramat | 5/30 (16.67%) |
| Ethosuximide | 5/30 (16.67%) |
| Vigabatrin | 4/30 (13.33%) |
| Lamotrigin | 3/30 (10.00%) |
| Rufinamide | 1/30 (3.33%) |
| Zonisamide | 1/30 (3.33%) |
|
| |
| Sleep history (parent report) | |
| Never/seldom sleeps restlessly | 23/31 (74.1%) |
| Never/seldom stops breathing in sleep | 23/31 (74.1%) |
| Daily drowsiness | 25/31 (80.64%) |
|
| |
| Encephalographic epileptiform activity | |
| Interictal | 31/31 (100%) |
| Ictal events | 4/31 (12.9%) |
Values are expressed as absolute numbers and percentage, unless otherwise specified. Children in the epileptic encephalopathy and control group were matched for sex, age (p=0.98) and BMI (p=0.26).
Differences in sleep structure, respiratory parameters and sat02 between the group of children with epileptic encephalopathies and the control group.
| V-PSG parameter | Children with EE (N=31) | Control group (N=31) | Mann Whitney U test | |
|---|---|---|---|---|
| U | p-Value | |||
| TRT (min) | 462.00 (432.50–499.25) | 486.00 (460.25–506.25) | 364.00 | 0.101 |
| TST (min) | 395.00 (326.25–429.25) | 414.00 (395.25–432.75) | 333.50 | |
| SE (%) | 82.99 (70.81–88.90) | 87.30 (81.70–90.74) | 369.00 | 0.116 |
| SL (min) | 27.00 (11.25–45.12) | 23.00 (11.25–43.00) | 459.00 | 0.761 |
| RL (min) | 124.00 (69.00–177.00) | 109.50 (74.00–147.00) | 392.00 | 0.391 |
| TWT (min) | 45.00 (17.25–74.50) | 24.00 (18.00–48.00) | 407.50 | 0.304 |
| Sleep efficiency (%) | 88.16 (77.65–96.46) | 93.08 (87.57–96.40) | 368.00 | 0.113 |
| N1% | 2.10 (1.10–3.08) | 1.40 (1.03–1.88) | 329.00 | 0.033 |
| N2% | 46.60 (31.53–53.98) | 43.10 (37.10–48.43) | 448.00 | 0.647 |
| N3% | 27.90 (17.55–44.70) | 31.60 (26.17–33.85) | 408.00 | 0.307 |
| REM% | 13.80 (8.40–16.78) | 19.80 (17.60–22.20) | 146.50 | |
| Number of arousals (N) | 7.5 (3.00–10.00) | 8.00 (6.00–10.00) | 286.00 | 0.340 |
| Number of respiratory events (N) | 0.00 (0.00–1.75) | 1.00 (1.00–1.75) | 374.50 | 0.118 |
| Average duration of respiratory events (s) | 0.00 (0.00–10.00) | 10.00 (8.25–12.00) | 297.00 | |
| Longest duration of respiratory events (s) | 0.00 (0.00–11.75) | 10.00 (8.25–12.00) | 343.50 | |
| Apnea-Hypopnea Index (AHI) | 0.00 (0.00–0.26) | 0.15 (0.12–0.24) | 404.50 | 0.27 |
| Average sat02 (%) | 98.00 (97.00–98.00) | 98.00 (98.00–99.00) | 296.00 | |
| Miminum sat02 (%) | 91.00 (90.00–94.00) | 93.00 (93.00–94.00) | 229.50 | |
Average rank.